Dr. Nicholas Robert on MA.17R Trial for Patients With Early-Stage Breast Cancer
Nicholas J. Robert, MD
Nicholas J. Robert, MD, medical oncology, hematology, Virginia Cancer Specialists, US Oncology, discusses the MA.17R trial, which explored an extension of adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.
The randomized trial was to evaluate how long treatment with aromatase inhibitors should be given to patients with early-stage breast cancer, Robert explains. Patients were randomized to receive continued use of letrozole or placebo after receiving 5 years of letrozole from the earlier MA.17 trial. Additional patients outside of the original trial who received the standard 5-year treatment of letrozole were also recruited to MA.17R.
Results showed that with 1900 patients and a 6-year follow-up, there was an improvement in disease-free survival in patients who continued treatment with letrozole versus placebo at 95% and 91%, respectively. There is no yet available data on overall survival, Robert adds.